Literature DB >> 25091625

DNA methylation and mRNA and microRNA expression of SLE CD4+ T cells correlate with disease phenotype.

Ming Zhao1, Siyang Liu2, Shuangyan Luo1, Honglong Wu2, Meini Tang1, Wenjing Cheng1, Qing Zhang1, Peng Zhang1, Xinhai Yu1, Yudong Xia2, Na Yi2, Fei Gao2, Li Wang2, Susan Yung3, Tak Mao Chan3, Amr H Sawalha4, Bruce Richardson4, M Eric Gershwin5, Ning Li6, Qianjin Lu7.   

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease well known for its clinical heterogeneity, and its etiology secondary to a cross-talk involving genetic predisposition and environmental stimuli. Although genome-wide analysis has contributed greatly to our understanding of the genetic basis of SLE, there is increasing evidence for a role of epigenetics. Indeed, recent data have demonstrated that in patients with SLE, there are striking alterations of DNA methylation, histone modifications, and deregulated microRNA expression, the sum of which contribute to over-expression of select autoimmune-related genes and loss of tolerance. To address this issue at the level of clinical phenotype, we performed DNA methylation, mRNA and microRNA expression screening using high-throughput sequencing of purified CD4+ T cells from patients with SLE, compared to age and sex matched controls. In particular, we studied 42 patients with SLE and divided this group into three clinical phenotypes: a) the presence of skin lesions without signs of systemic pathology; b) skin lesions but also chronic renal pathology; and c) skin lesions, chronic renal pathology and polyarticular disease. Interestingly, and as expected, sequencing data revealed changes in DNA methylation in SLE compared to controls. However, and more importantly, although there were common methylation changes found in all groups of SLE compared to controls, there was specific DNA methylation changes that correlated with clinical phenotype. These included changes in the novel key target genes NLRP2, CD300LB and S1PR3, as well as changes in the critical pathways, including the adherens junction and leukocyte transendothelial migration. We also noted that a significant proportion of genes undergoing DNA methylation changes were inversely correlated with gene expression and that miRNA screening revealed the existence of subsets with changes in expression. Integrated analysis of this data highlights specific sets of miRNAs controlled by DNA methylation, and genes that are altered by methylation and targeted by miRNAs. In conclusion, our findings suggest select epigenetic mechanisms that contribute to clinical phenotypes and further shed light on a new venue for basic SLE research.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DNA methylation; Epigenetics; Systemic lupus erythematosus; T cells; Transcriptome; microRNA

Mesh:

Substances:

Year:  2014        PMID: 25091625     DOI: 10.1016/j.jaut.2014.07.002

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  60 in total

1.  IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus.

Authors:  Ming Zhao; Yin Zhou; Bochen Zhu; Mengjie Wan; Tingting Jiang; Qiqun Tan; Yan Liu; Juqing Jiang; Shuaihantian Luo; Yixin Tan; Haijing Wu; Paul Renauer; Maria Del Mar Ayala Gutiérrez; Maria Jesús Castillo Palma; Rafaela Ortega Castro; Concepción Fernández-Roldán; Enrique Raya; Raquel Faria; Claudia Carvalho; Marta E Alarcón-Riquelme; Zhongyuan Xiang; Jinwei Chen; Fen Li; Guanghui Ling; Hongjun Zhao; Xiangping Liao; Youkun Lin; Amr H Sawalha; Qianjin Lu
Journal:  Ann Rheum Dis       Date:  2016-01-19       Impact factor: 19.103

2.  Microarray expression profile of circular RNAs and mRNAs in children with systemic lupus erythematosus.

Authors:  Shipeng Li; Junmei Zhang; Xiaohua Tan; Jianghong Deng; Yan Li; Yurong Piao; Chao Li; Wenxu Yang; Wenxiu Mo; Jiapeng Sun; Fei Sun; Tongxin Han; Jiang Wang; Weiying Kuang; Caifeng Li
Journal:  Clin Rheumatol       Date:  2019-01-09       Impact factor: 2.980

3.  Ultraviolet B decreases DNA methylation level of CD4+ T cells in patients with systemic lupus erythematosus.

Authors:  Min Zhang; Xuan Fang; Guo-Sheng Wang; Yan Ma; Li Jin; Xiao-Mei Li; Xiang-Pei Li
Journal:  Inflammopharmacology       Date:  2017-02-11       Impact factor: 4.473

4.  Renal involvement in lupus is characterized by unique DNA methylation changes in naïve CD4+ T cells.

Authors:  Patrick Coit; Paul Renauer; Matlock A Jeffries; Joan T Merrill; W Joseph McCune; Kathleen Maksimowicz-McKinnon; Amr H Sawalha
Journal:  J Autoimmun       Date:  2015-05-23       Impact factor: 7.094

Review 5.  Epigenetic Variability in Systemic Lupus Erythematosus: What We Learned from Genome-Wide DNA Methylation Studies.

Authors:  Maria Teruel; Amr H Sawalha
Journal:  Curr Rheumatol Rep       Date:  2017-06       Impact factor: 4.592

6.  Hypomethylation of STAT1 and HLA-DRB1 is associated with type-I interferon-dependent HLA-DRB1 expression in lupus CD8+ T cells.

Authors:  Shaylynn Miller; Pei-Suen Tsou; Patrick Coit; Elizabeth Gensterblum-Miller; Paul Renauer; Dallas M Rohraff; Nathan C Kilian; Mark Schonfeld; Amr H Sawalha
Journal:  Ann Rheum Dis       Date:  2019-01-23       Impact factor: 19.103

Review 7.  Microarray to deep sequencing: transcriptome and miRNA profiling to elucidate molecular pathways in systemic lupus erythematosus.

Authors:  Geeta Rai; Richa Rai; Amir Hossein Saeidian; Madhukar Rai
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

8.  Unmet challenges in immune-mediated hepatobiliary diseases.

Authors:  Ulrich Beuers; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 9.  DNA methylation alterations in the pathogenesis of lupus.

Authors:  S H Chen; Q L Lv; L Hu; M J Peng; G H Wang; B Sun
Journal:  Clin Exp Immunol       Date:  2016-11-01       Impact factor: 4.330

Review 10.  Genetics of human lupus nephritis.

Authors:  Taro Iwamoto; Timothy B Niewold
Journal:  Clin Immunol       Date:  2016-09-28       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.